Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity

E. coli O157:H7 is a foodborne pathogen responsible for bloody diarrhea, hemorrhagic colitis and hemolytic uremic syndrome (HUS). The objective of the present work was to evaluate the ability of colostral IgG obtained from Stx2-immunized cows to prevent against E. coli O157:H7 infection and Stx2 cytotoxicity. Hyperimmune colostrum (HC) was obtained from cows intramuscularly immunized with inactivated Stx2 or vehicle for controls. Colostral IgG was purified by affinity chromatography. Specific IgG antibodies against Stx2 and bovine lactoferrin (bLF) levels in HC and the corresponding IgG (HC-IgG/bLF) were determined by ELISA. The protective effects of HC-IgG/bLF against Stx2 cytotoxicity and adhesion of E. coli O157:H7 and its Stx2-negative mutant were analyzed in HCT-8 cells. HC-IgG/bLF prevention against E. coli O157:H7 was studied in human colon and rat colon loops. Protection against a lethal dose of E. coli O157:H7 was evaluated in a weaned mice model. HC-IgG/bLF showed high anti-Stx2 titers and high bLF levels that were able to neutralize the cytotoxic effects of Stx2 in vitro and in vivo. Furthermore, HC-IgG/bLF avoided the inhibition of water absorption induced by E. coli O157:H7 in human colon and also the pathogenicity of E. coli O157:H7 and E. coli O157:H7Dstx2 in rat colon loops. Finally, HC-IgG/ bLF prevented in a 100% the lethality caused by E. coli O157:H7 in a weaned mice model. Our study suggests that HC-IgG/bLF have protective effects against E. coli O157:H7 infection. These beneficial effects may be due to specific anti-Stx2 neutralizing antibodies in combination with high bLF levels. These results allow us to consider HC-IgG/bLF as a nutraceutical tool which could be used in combination with balanced supportive diets to prevent HUS. However further studies are required before recommendations can be made for therapeutic and clinical applications.

Saved in:
Bibliographic Details
Main Authors: Albanese, Adriana Andrea, Sacerdoti, Flavia, Seyahian, E. Abril, Amaral, María Marta, Fiorentino, Gabriela, Fernández Brando, Romina, Vilte, Daniel Alejandro, Mercado, Elsa Cristina, Palermo, Marina Sandra, Cataldi, Angel Adrian, Zotta, Elsa, Ibarra, Cristina Adriana
Format: info:eu-repo/semantics/article biblioteca
Language:eng
Published: 2018-03
Subjects:Vaca, Gestación, Vacunación, Escherichia Coli, Anticuerpos, Lactoferrinas, Inmunización, Cows, Pregnancy, Vaccination, Antibodies, Lactoferrin, Immunization,
Online Access:http://hdl.handle.net/20.500.12123/2151
https://www.sciencedirect.com/science/article/pii/S0264410X18302470
https://doi.org/10.1016/j.vaccine.2018.02.060
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:localhost:20.500.12123-2151
record_format koha
institution INTA AR
collection DSpace
country Argentina
countrycode AR
component Bibliográfico
access En linea
databasecode dig-inta-ar
tag biblioteca
region America del Sur
libraryname Biblioteca Central del INTA Argentina
language eng
topic Vaca
Gestación
Vacunación
Escherichia Coli
Anticuerpos
Lactoferrinas
Inmunización
Cows
Pregnancy
Vaccination
Antibodies
Lactoferrin
Immunization
Vaca
Gestación
Vacunación
Escherichia Coli
Anticuerpos
Lactoferrinas
Inmunización
Cows
Pregnancy
Vaccination
Antibodies
Lactoferrin
Immunization
spellingShingle Vaca
Gestación
Vacunación
Escherichia Coli
Anticuerpos
Lactoferrinas
Inmunización
Cows
Pregnancy
Vaccination
Antibodies
Lactoferrin
Immunization
Vaca
Gestación
Vacunación
Escherichia Coli
Anticuerpos
Lactoferrinas
Inmunización
Cows
Pregnancy
Vaccination
Antibodies
Lactoferrin
Immunization
Albanese, Adriana Andrea
Sacerdoti, Flavia
Seyahian, E. Abril
Amaral, María Marta
Fiorentino, Gabriela
Fernández Brando, Romina
Vilte, Daniel Alejandro
Mercado, Elsa Cristina
Palermo, Marina Sandra
Cataldi, Angel Adrian
Zotta, Elsa
Ibarra, Cristina Adriana
Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity
description E. coli O157:H7 is a foodborne pathogen responsible for bloody diarrhea, hemorrhagic colitis and hemolytic uremic syndrome (HUS). The objective of the present work was to evaluate the ability of colostral IgG obtained from Stx2-immunized cows to prevent against E. coli O157:H7 infection and Stx2 cytotoxicity. Hyperimmune colostrum (HC) was obtained from cows intramuscularly immunized with inactivated Stx2 or vehicle for controls. Colostral IgG was purified by affinity chromatography. Specific IgG antibodies against Stx2 and bovine lactoferrin (bLF) levels in HC and the corresponding IgG (HC-IgG/bLF) were determined by ELISA. The protective effects of HC-IgG/bLF against Stx2 cytotoxicity and adhesion of E. coli O157:H7 and its Stx2-negative mutant were analyzed in HCT-8 cells. HC-IgG/bLF prevention against E. coli O157:H7 was studied in human colon and rat colon loops. Protection against a lethal dose of E. coli O157:H7 was evaluated in a weaned mice model. HC-IgG/bLF showed high anti-Stx2 titers and high bLF levels that were able to neutralize the cytotoxic effects of Stx2 in vitro and in vivo. Furthermore, HC-IgG/bLF avoided the inhibition of water absorption induced by E. coli O157:H7 in human colon and also the pathogenicity of E. coli O157:H7 and E. coli O157:H7Dstx2 in rat colon loops. Finally, HC-IgG/ bLF prevented in a 100% the lethality caused by E. coli O157:H7 in a weaned mice model. Our study suggests that HC-IgG/bLF have protective effects against E. coli O157:H7 infection. These beneficial effects may be due to specific anti-Stx2 neutralizing antibodies in combination with high bLF levels. These results allow us to consider HC-IgG/bLF as a nutraceutical tool which could be used in combination with balanced supportive diets to prevent HUS. However further studies are required before recommendations can be made for therapeutic and clinical applications.
format info:eu-repo/semantics/article
topic_facet Vaca
Gestación
Vacunación
Escherichia Coli
Anticuerpos
Lactoferrinas
Inmunización
Cows
Pregnancy
Vaccination
Antibodies
Lactoferrin
Immunization
author Albanese, Adriana Andrea
Sacerdoti, Flavia
Seyahian, E. Abril
Amaral, María Marta
Fiorentino, Gabriela
Fernández Brando, Romina
Vilte, Daniel Alejandro
Mercado, Elsa Cristina
Palermo, Marina Sandra
Cataldi, Angel Adrian
Zotta, Elsa
Ibarra, Cristina Adriana
author_facet Albanese, Adriana Andrea
Sacerdoti, Flavia
Seyahian, E. Abril
Amaral, María Marta
Fiorentino, Gabriela
Fernández Brando, Romina
Vilte, Daniel Alejandro
Mercado, Elsa Cristina
Palermo, Marina Sandra
Cataldi, Angel Adrian
Zotta, Elsa
Ibarra, Cristina Adriana
author_sort Albanese, Adriana Andrea
title Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity
title_short Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity
title_full Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity
title_fullStr Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity
title_full_unstemmed Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity
title_sort immunization of pregnant cows with shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize e. coli o157:h7 pathogenicity
publishDate 2018-03
url http://hdl.handle.net/20.500.12123/2151
https://www.sciencedirect.com/science/article/pii/S0264410X18302470
https://doi.org/10.1016/j.vaccine.2018.02.060
work_keys_str_mv AT albaneseadrianaandrea immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT sacerdotiflavia immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT seyahianeabril immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT amaralmariamarta immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT fiorentinogabriela immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT fernandezbrandoromina immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT viltedanielalejandro immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT mercadoelsacristina immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT palermomarinasandra immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT cataldiangeladrian immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT zottaelsa immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
AT ibarracristinaadriana immunizationofpregnantcowswithshigatoxin2induceshighlevelsofspecificcolostralantibodiesandlactoferrinabletoneutralizeecolio157h7pathogenicity
_version_ 1756007090936086528
spelling oai:localhost:20.500.12123-21512018-04-03T13:09:49Z Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity Albanese, Adriana Andrea Sacerdoti, Flavia Seyahian, E. Abril Amaral, María Marta Fiorentino, Gabriela Fernández Brando, Romina Vilte, Daniel Alejandro Mercado, Elsa Cristina Palermo, Marina Sandra Cataldi, Angel Adrian Zotta, Elsa Ibarra, Cristina Adriana Vaca Gestación Vacunación Escherichia Coli Anticuerpos Lactoferrinas Inmunización Cows Pregnancy Vaccination Antibodies Lactoferrin Immunization E. coli O157:H7 is a foodborne pathogen responsible for bloody diarrhea, hemorrhagic colitis and hemolytic uremic syndrome (HUS). The objective of the present work was to evaluate the ability of colostral IgG obtained from Stx2-immunized cows to prevent against E. coli O157:H7 infection and Stx2 cytotoxicity. Hyperimmune colostrum (HC) was obtained from cows intramuscularly immunized with inactivated Stx2 or vehicle for controls. Colostral IgG was purified by affinity chromatography. Specific IgG antibodies against Stx2 and bovine lactoferrin (bLF) levels in HC and the corresponding IgG (HC-IgG/bLF) were determined by ELISA. The protective effects of HC-IgG/bLF against Stx2 cytotoxicity and adhesion of E. coli O157:H7 and its Stx2-negative mutant were analyzed in HCT-8 cells. HC-IgG/bLF prevention against E. coli O157:H7 was studied in human colon and rat colon loops. Protection against a lethal dose of E. coli O157:H7 was evaluated in a weaned mice model. HC-IgG/bLF showed high anti-Stx2 titers and high bLF levels that were able to neutralize the cytotoxic effects of Stx2 in vitro and in vivo. Furthermore, HC-IgG/bLF avoided the inhibition of water absorption induced by E. coli O157:H7 in human colon and also the pathogenicity of E. coli O157:H7 and E. coli O157:H7Dstx2 in rat colon loops. Finally, HC-IgG/ bLF prevented in a 100% the lethality caused by E. coli O157:H7 in a weaned mice model. Our study suggests that HC-IgG/bLF have protective effects against E. coli O157:H7 infection. These beneficial effects may be due to specific anti-Stx2 neutralizing antibodies in combination with high bLF levels. These results allow us to consider HC-IgG/bLF as a nutraceutical tool which could be used in combination with balanced supportive diets to prevent HUS. However further studies are required before recommendations can be made for therapeutic and clinical applications. Inst. de Patobiología Fil: Albanese, Adriana Andrea. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas. Laboratorio de Fisiopatogenia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Fisiología y Biofísica Bernardo Houssay. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica Bernardo Houssay; Argentina Fil: Sacerdoti, Flavia. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas. Laboratorio de Fisiopatogenia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Fisiología y Biofísica Bernardo Houssay. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica Bernardo Houssay; Argentina Fil: Seyahian, E. Abril. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas. Laboratorio de Fisiopatogenia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Fisiología y Biofísica Bernardo Houssay. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica Bernardo Houssay; Argentina Fil: Amaral, María Marta. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas. Laboratorio de Fisiopatogenia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Fisiología y Biofísica Bernardo Houssay. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica Bernardo Houssay; Argentina Fil: Fiorentino, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina. Academia Nacional de Medicina de Buenos Aires. Laboratorio de Patogénesis e Inmunología de Procesos Infecciosos; Argentina Fil: Fernández Brando, Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina. Academia Nacional de Medicina de Buenos Aires. Laboratorio de Patogénesis e Inmunología de Procesos Infecciosos; Argentina Fil: Vilte, Daniel Alejandro. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina Fil: Mercado, Elsa Cristina. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina Fil: Palermo, Marina Sandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina. Academia Nacional de Medicina de Buenos Aires. Laboratorio de Patogénesis e Inmunología de Procesos Infecciosos; Argentina Fil: Cataldi, Angel Adrian. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentina Fil: Zotta, Elsa. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas. Laboratorio de Fisiopatogenia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Fisiología y Biofísica Bernardo Houssay. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica Bernardo Houssay; Argentina Fil: Ibarra, Cristina Adriana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Fisiología y Biofísica Bernardo Houssay. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica Bernardo Houssay; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas. Laboratorio de Fisiopatogenia; Argentina 2018-04-03T12:09:54Z 2018-04-03T12:09:54Z 2018-03 info:eu-repo/semantics/article info:ar-repo/semantics/artículo info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/2151 https://www.sciencedirect.com/science/article/pii/S0264410X18302470 0264-410X https://doi.org/10.1016/j.vaccine.2018.02.060 eng info:eu-repo/semantics/restrictedAccess application/pdf Vaccine 36 (13) : 1728-1735 (March 2018)